NIH Applicants Adapt To Study-Population Inclusion Guidelines

A federal law requiring National Institutes of Health-funded disease studies to show an adequate representation of women, minorities, and racial and ethnic subgroups is forcing researchers to adopt novel methods of inclusion. These methods often go far beyond incorporating minority groups into their research design plans. Means that investigators have adopted to attract and retain populations that conform to the new law include buying lunch, paying bus fare, opening satellite clinics, even goin

Written byMyrna Watanabe
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

A federal law requiring National Institutes of Health-funded disease studies to show an adequate representation of women, minorities, and racial and ethnic subgroups is forcing researchers to adopt novel methods of inclusion. These methods often go far beyond incorporating minority groups into their research design plans. Means that investigators have adopted to attract and retain populations that conform to the new law include buying lunch, paying bus fare, opening satellite clinics, even going cross-country to find some groups.

But while innovative researchers and clinicians work to accommodate these NIH inclusion guidelines, as they are called, debate continues about whether institution of these rules represents good science, appropriate social policy, or simply justice.

The law, included in the NIH Revitalization Act of 1993, is an outgrowth of similar NIH regulations adopted in 1986 and 1987 and revised in 1990. All new grant proposals involving human subjects are required to include women, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies